Granulomatose avec polyangéite : Questions médicales fréquentes
Nom anglais: Granulomatosis with Polyangiitis
Descriptor UI:D014890
Tree Number:C20.111.193.875
Termes MeSH sélectionnés :
Pemphigus
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Granulomatose avec polyangéite : Questions médicales les plus fréquentes",
"headline": "Granulomatose avec polyangéite : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Granulomatose avec polyangéite : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-23",
"dateModified": "2025-02-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Granulomatose avec polyangéite"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"url": "https://questionsmedicales.fr/mesh/D056648",
"about": {
"@type": "MedicalCondition",
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"code": {
"@type": "MedicalCode",
"code": "D056648",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.111.193"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Granulomatose avec polyangéite",
"alternateName": "Granulomatosis with Polyangiitis",
"code": {
"@type": "MedicalCode",
"code": "D014890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Benjamin Terrier",
"url": "https://questionsmedicales.fr/author/Benjamin%20Terrier",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France benjamin.terrier@aphp.fr."
}
},
{
"@type": "Person",
"name": "Xavier Puéchal",
"url": "https://questionsmedicales.fr/author/Xavier%20Pu%C3%A9chal",
"affiliation": {
"@type": "Organization",
"name": "Centre de Référence des Maladies Systémiques Auto-immunes rares, Université Paris Descartes, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris, France. Electronic address: xavier.puechal@aphp.fr."
}
},
{
"@type": "Person",
"name": "Christian Pagnoux",
"url": "https://questionsmedicales.fr/author/Christian%20Pagnoux",
"affiliation": {
"@type": "Organization",
"name": "Vasculitis Clinic, Division of Rheumatology, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada."
}
},
{
"@type": "Person",
"name": "Roman Yatsyshyn",
"url": "https://questionsmedicales.fr/author/Roman%20Yatsyshyn",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine #1, Clinical Immunology and Allergology Named After Academician Ye. M. Neiko, Ivano-Frankivsk National Medical University, Halytska str. 2, Ivano-Frankivsk, 76000, Ukraine."
}
},
{
"@type": "Person",
"name": "Olena Zimba",
"url": "https://questionsmedicales.fr/author/Olena%20Zimba",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Taiwanese dermatological association (TDA) consensus for the management of pemphigus.",
"datePublished": "2022-12-21",
"url": "https://questionsmedicales.fr/article/36564301",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jfma.2022.12.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Rare Case of Paraneoplastic Pemphigus Associated With Prostatic Cancer.",
"datePublished": "2022-09-27",
"url": "https://questionsmedicales.fr/article/36197045",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/DAD.0000000000002313"
}
},
{
"@type": "ScholarlyArticle",
"name": "Topical care in pemphigus wounds: A systematic review of the literature.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/36070217",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/dth.15808"
}
},
{
"@type": "ScholarlyArticle",
"name": "Current biologics in treatment of pemphigus foliaceus: a systematic review.",
"datePublished": "2023-10-12",
"url": "https://questionsmedicales.fr/article/37901249",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1267668"
}
},
{
"@type": "ScholarlyArticle",
"name": "FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.",
"datePublished": "2022-05-18",
"url": "https://questionsmedicales.fr/article/35663943",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.863095"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies auto-immunes",
"item": "https://questionsmedicales.fr/mesh/D001327"
},
{
"@type": "ListItem",
"position": 4,
"name": "Vascularites associées aux anticorps anti-cytoplasme des neutrophiles",
"item": "https://questionsmedicales.fr/mesh/D056648"
},
{
"@type": "ListItem",
"position": 5,
"name": "Granulomatose avec polyangéite",
"item": "https://questionsmedicales.fr/mesh/D014890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Granulomatose avec polyangéite - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Granulomatose avec polyangéite",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Granulomatose avec polyangéite",
"description": "Comment diagnostiquer la granulomatose avec polyangéite ?\nQuels tests sanguins sont utilisés pour le diagnostic ?\nQuel rôle joue la biopsie dans le diagnostic ?\nQuels symptômes cliniques orientent vers cette maladie ?\nComment les examens d'imagerie aident-ils au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Pemphigus&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Granulomatose avec polyangéite",
"description": "Quels sont les symptômes courants de cette maladie ?\nLa granulomatose affecte-t-elle les voies respiratoires ?\nQuels problèmes rénaux peuvent survenir ?\nY a-t-il des manifestations cutanées ?\nLes symptômes varient-ils d'un patient à l'autre ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Pemphigus&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Granulomatose avec polyangéite",
"description": "Peut-on prévenir la granulomatose avec polyangéite ?\nComment éviter les complications ?\nLes vaccinations sont-elles recommandées ?\nY a-t-il des conseils de mode de vie à suivre ?\nLes patients doivent-ils éviter certains médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Pemphigus&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Granulomatose avec polyangéite",
"description": "Quels traitements sont utilisés pour cette maladie ?\nComment les corticostéroïdes aident-ils ?\nQuels sont les effets secondaires des traitements ?\nLa thérapie biologique est-elle une option ?\nQuelle est l'importance du suivi médical ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Pemphigus&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Granulomatose avec polyangéite",
"description": "Quelles sont les complications possibles ?\nComment l'insuffisance rénale se manifeste-t-elle ?\nLes infections sont-elles fréquentes ?\nQuels problèmes pulmonaires peuvent survenir ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Pemphigus&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Granulomatose avec polyangéite",
"description": "Quels sont les facteurs de risque connus ?\nLe tabagisme augmente-t-il le risque ?\nLes infections peuvent-elles déclencher la maladie ?\nY a-t-il un lien avec d'autres maladies auto-immunes ?\nL'âge influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D014890?mesh_terms=Pemphigus&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la granulomatose avec polyangéite ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins, des biopsies et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la recherche d'anticorps anti-PR3 et des marqueurs d'inflammation."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet d'identifier les granulomes et l'inflammation des vaisseaux."
}
},
{
"@type": "Question",
"name": "Quels symptômes cliniques orientent vers cette maladie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs articulaires, des éruptions cutanées et des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Comment les examens d'imagerie aident-ils au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les examens comme la radiographie ou l'IRM montrent des anomalies dans les poumons et les reins."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de cette maladie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, perte de poids, et douleurs musculaires."
}
},
{
"@type": "Question",
"name": "La granulomatose affecte-t-elle les voies respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut provoquer des sinusites, des saignements de nez et des toux persistantes."
}
},
{
"@type": "Question",
"name": "Quels problèmes rénaux peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des atteintes rénales peuvent entraîner une insuffisance rénale et des urines anormales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des manifestations cutanées ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées, des nodules et des ulcères peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'un patient à l'autre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la combinaison des symptômes peuvent varier considérablement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la granulomatose avec polyangéite ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical peut aider."
}
},
{
"@type": "Question",
"name": "Comment éviter les complications ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement précoce et un suivi régulier permettent de réduire le risque de complications."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent être recommandées pour prévenir certaines infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils de mode de vie à suivre ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est conseillé."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains médicaments ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent aggraver la maladie et doivent être évités."
}
},
{
"@type": "Question",
"name": "Quels traitements sont utilisés pour cette maladie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs pour réduire l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les corticostéroïdes aident-ils ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils réduisent l'inflammation et soulagent les symptômes rapidement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des infections, des troubles digestifs et des problèmes osseux."
}
},
{
"@type": "Question",
"name": "La thérapie biologique est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des thérapies biologiques ciblées peuvent être utilisées pour les cas réfractaires."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du suivi médical ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier est crucial pour ajuster le traitement et surveiller les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance rénale, les infections et les problèmes pulmonaires."
}
},
{
"@type": "Question",
"name": "Comment l'insuffisance rénale se manifeste-t-elle ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par une diminution de la production d'urine et un gonflement."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients sont plus susceptibles de développer des infections en raison du traitement."
}
},
{
"@type": "Question",
"name": "Quels problèmes pulmonaires peuvent survenir ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications pulmonaires peuvent inclure des hémorragies et des nodules pulmonaires."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite un suivi médical étroit et des ajustements de traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque connus ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, le tabagisme et certaines infections."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque significatif pour cette maladie."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles déclencher la maladie ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections, comme celles des voies respiratoires, peuvent être des déclencheurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec d'autres maladies auto-immunes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes atteintes d'autres maladies auto-immunes peuvent avoir un risque accru."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "La maladie est plus fréquente chez les adultes jeunes à moyens, généralement entre 30 et 60 ans."
}
}
]
}
]
}
Pemphigus is an uncommon but life-threatening autoimmune blistering disease characterized by the presence of antibodies against desmogleins. Without effective treatment, pemphigus can result in signif...
The combination of paraneoplastic pemphigus and prostate cancer is extremely unusual and has not been reported yet. Paraneoplastic pemphigus is caused by tumor-induced autoantibodies, which cause dama...
Pemphigus is a group of autoimmune blistering diseases. Given the ulcerative nature of the diseases, the full healing of ulcers and erosions might be challenging. The aim of this study was to determin...
Pemphigus foliaceus (PF) differs from pemphigus vulgaris (PV) in that it affects only the skin and mucous membranes are not involved. Pemphigus is commonly treated with systemic corticosteroids and im...
A search of PubMed, Embase, and other databases was conducted using keywords pemphigus foliaceus (PF), rituximab (RTX), intravenous immunoglobulin (IVIg), and biologics. Forty-one studies were include...
Most patients in this review had PF that was nonresponsive to conventional immunosuppressive therapies (CIST), and had significant side effects from their use. RTX treatment resulted in complete remis...
In pemphigus foliaceus patients nonresponsive to conventional immunosuppressive therapy or in those with significant side effects from CIST, RTX and IVIg appear to be useful agents. Profile of clinica...
Immunoglobulin G (IgG) levels are maintained by the IgG-recycling neonatal Fc-receptor (FcRn). Pemphigus vulgaris and pemphigus foliaceus are debilitating autoimmune disorders triggered by IgG autoant...
The aim of our study was to assess the impact of FcRn antagonism by efgartigimod on immunological parameters known to be directly involved in pemphigus pathology, such as cellular and serological resp...
We investigated total and antigen-specific IgG subclass level kinetics during and after treatment, assessed antigen-specific B-cell responses, followed T- and B-cell immunophenotypes, and analyzed how...
Treatment resulted in reduction of total IgG as well as autoreactive IgG antibody levels. Surprisingly, unlike total IgG and vaccine- or natural-infection-elicited IgG, which returned to baseline leve...
Efgartigimod treatment of participants with pemphigus improved their conditions and exerted an immunomodulatory effect beyond the blockade of IgG recycling. Further studies in larger populations with ...
Pemphigus is an autoimmune blistering disease with two major subtypes, pemphigus vulgaris (PV) and pemphigus foliaceus (PF). Although most patients with PV show oral lesions, cutaneous type PV (C-PV) ...
Paraneoplastic pemphigus (PNP) is a rare autoimmune skin disease closely related to tumors, characterized by a maculopapular rash with mucosal pain, bronchiole occlusion, and respiratory failure may o...
Molecular mechanisms underlying auto-antibody-induced acantholysis in pemphigus vulgaris are subject of current research to date. To decipher the discrepancy between ubiquitous antibody binding to the...
Although the treatment for pemphigus vulgaris (PV) has been revolutionized by the use of rituximab combined with corticosteroids, new effective therapies with a better safety profile are needed....
A 67-year-old woman was diagnosed with severe mucosal PV, which was initially misdiagnosed as atypical Behçet's disease. Following an unsuccessful colchicine treatment, significant improvement was obs...
Apremilast, a phosphodiesterase 4 inhibitor approved for psoriasis and Behçet's disease's related oral ulcers treatment, demonstrated its efficacy in this PV case. This is the second case report highl...
Apremilast may be a promising therapeutic option for the treatment of pemphigus, with an innovative mechanism of action, no induced immunosuppression, and good tolerance. It could be a good alternativ...
Paraneoplastic pemphigus (PNP) is a rare, often fatal, autoimmune blistering disease of the skin and mucous membranes. In children, PNP is frequently associated with Castleman disease (CD). This serie...
Data were collected retrospectively from the medical records of patients with a diagnosis of PNP and CD from January 2013 to June 2022. Patients ≤22 years old with clinical and immunopathologic eviden...
Two children, two adolescents, and one young adult (two males, three females) were included. The average age at disease presentation was 11.8 years (range: 7-22 years). Oral (n = 5) and anogenital (n ...
Most patients had UCD, and the retroperitoneum was the most common location. Patients with MCD, incomplete resection, and BO died; patients with UCD and complete resection remain alive, even in the se...